Douglas Miehm
Stock Analyst at RBC Capital
(3.40)
# 985
Out of 5,031 analysts
47
Total ratings
52.38%
Success rate
4.64%
Average return
Main Sectors:
Stocks Rated by Douglas Miehm
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MNKD MannKind | Maintains: Outperform | $7 → $8 | $5.47 | +46.25% | 3 | Aug 26, 2025 | |
| AUPH Aurinia Pharmaceuticals | Maintains: Outperform | $8 → $9 | $11.55 | -22.08% | 10 | Aug 1, 2025 | |
| BHC Bausch Health Companies | Maintains: Sector Perform | $8.5 → $10 | $6.05 | +65.29% | 20 | May 2, 2025 | |
| BLCO Bausch + Lomb | Maintains: Outperform | $18 → $17 | $15.00 | +13.33% | 13 | Apr 4, 2025 | |
| ONCY Oncolytics Biotech | Maintains: Outperform | $6 → $5 | $1.18 | +323.73% | 1 | Mar 10, 2025 |
MannKind
Aug 26, 2025
Maintains: Outperform
Price Target: $7 → $8
Current: $5.47
Upside: +46.25%
Aurinia Pharmaceuticals
Aug 1, 2025
Maintains: Outperform
Price Target: $8 → $9
Current: $11.55
Upside: -22.08%
Bausch Health Companies
May 2, 2025
Maintains: Sector Perform
Price Target: $8.5 → $10
Current: $6.05
Upside: +65.29%
Bausch + Lomb
Apr 4, 2025
Maintains: Outperform
Price Target: $18 → $17
Current: $15.00
Upside: +13.33%
Oncolytics Biotech
Mar 10, 2025
Maintains: Outperform
Price Target: $6 → $5
Current: $1.18
Upside: +323.73%